Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT02013817
- Locations
- 🇦🇹
LKH Hochsteiermark; Abt. für Innere Medizin, Leoben, Austria
🇦🇹Kh Der Barmherzigen Schwestern; Interne I X, Linz, Austria
🇦🇹A.Ö. Krankenhaus Der Elisabethinen Linz; I. Interne Abt., Linz, Austria
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT02013765
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 285
- Registration Number
- NCT02011334
A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02010216
Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 532
- Registration Number
- NCT02008266
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1225
- Registration Number
- NCT02008227
- Locations
- 🇺🇸
Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸Roy & Patricia Disney Family Cancer Center, Burbank, California, United States
🇺🇸St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
- Conditions
- Urinary Tract Cancer
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT02006667
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT02006706
OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 252
- Registration Number
- NCT02005562
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 389
- Registration Number
- NCT02005471
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, Belgium
🇺🇸Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia